Akèy › Kansè Poumon ki pa ti selil › Michigan
Etid klinik pou Kansè Poumon ki pa ti selil nan Michigan
101 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan Michigan.
Vil nan Michigan
- Grand Rapids44 etid
- Detroit44 etid
- Ann Arbor26 etid
- Farmington Hills13 etid
- Flint9 etid
- Lansing9 etid
- Livonia8 etid
- Canton8 etid
- Waterford8 etid
- Saginaw7 etid
- Wyoming6 etid
- Kalamazoo6 etid
- Dearborn6 etid
- Norton Shores5 etid
- Clinton Township4 etid
- Muskegon4 etid
- Warren4 etid
- Troy3 etid
Tèks ofisyèl etid la (Anglè)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- ak 50 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- ak 7 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07293247A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #65, Detroit
- Exelixis Clinical Site #13, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- BAMF Health, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07189871Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Bronson Battle Creek, Battle Creek
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Bronson Methodist Hospital, Kalamazoo
- ak 7 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07388524Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- ak 38 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06498635A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Research Site, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06996782A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 8, Farmington Hills
- ALX Center 3, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07085091A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07361497Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Henry Ford Hospital - Detroit /ID# 271642, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Trinity Health Ann Arbor Hospital, Ann Arbor
- Karmanos Cancer Institute, Detroit
- Henry Ford Health, Detroit
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06881784This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Corewell Health - Butterworth Hospital, Grand Rapids
- Corewell Health - Lemmen Holton Cancer Pavilion, Grand Rapids
- Corewell Health - Research Specimen Processing Area, Grand Rapids
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Michigan Health System, Ann Arbor
- Trinity Health St Joseph Mercy Ann Arbor, Ypsilanti
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667076A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Saginaw
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06868277Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06890598Pan-tumor MRD Study
- The Cancer & Hematology Centers (CHC), Grand Rapids
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- ak 48 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03191149A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Profound Research LLC - MHP MedOnc Royal Oak - Oakland Medical Group Location, Royal Oak
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06561386Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Dearborn
- Research Site, Farmington Hills
- Research Site, Grand Rapids
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06357533A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- University of Michigan Health Systems, Ann Arbor
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07140016Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Barbara Ann Karmanos Cancer Center, Detroit
- START Midwest, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07488676A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Local Institution - 0293, Detroit
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06875310A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07629960A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Detroit
- Research Site, Grand Rapids
- Research Site, Saginaw
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Ann Arbor
- Clinical Study Site, Detroit
- Clinical Study Sites, Detroit
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06767514A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06855771Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- START Midwest, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- START Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07349537A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- BAMF Health, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07020117Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05786924Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Cancer & Hematology Centers of Western Michigan - East /ID# 261826, Grand Rapids
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06236438ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- University of Michigan, Ann Arbor
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT04302025A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- START | Midwest, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06914128A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University of Michigan, Ann Arbor
- Henry Ford Cancer Institute, Detroit
- START - Midwest Cancer Research Center, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Profound Research, LLC, Farmington Hills
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07541170A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Profound Research, LLC, Farmington Hills
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06793215Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.